DXCM Stock Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DXCM from our risk checks.
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.50 |
| 52 Week High | US$139.55 |
| 52 Week Low | US$78.94 |
| Beta | 1.12 |
| 1 Month Change | -13.35% |
| 3 Month Change | -30.97% |
| 1 Year Change | 8.48% |
| 3 Year Change | -13.01% |
| 5 Year Change | 144.69% |
| Change since IPO | 2,881.26% |
Recent News & Updates
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14Recent updates
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Jun 05There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital
May 16Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?
Mar 21These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Mar 03DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price
Feb 13DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly
Nov 25Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)
Oct 21Dexcom launches G7 glucose monitoring system in parts of Europe, Asia
Oct 04What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?
Sep 24DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend
Sep 21DexCom promotes technology chief Leach to COO
Aug 31DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet
Aug 01DexCom stock down ~7% after hours as Q2 results miss expectations
Jul 28Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)
Jul 13DexCom: I Wouldn't Buy The Dip
Jul 07Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?
Jun 24We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)
Jun 03DexCom: Q1'22 Earnings Strong Enough To Maintain Valuation But Not To Increase It
May 01DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly
Apr 12DexCom, Inc. (NASDAQ:DXCM) Shares Could Be 21% Below Their Intrinsic Value Estimate
Mar 28Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)
Feb 03DexCom: Buy The Dip For Robust Product Portfolio And Healthy Financials
Feb 01Is Now The Time To Put DexCom (NASDAQ:DXCM) On Your Watchlist?
Dec 30DexCom: Fast Growing Medical Device Company For Diabetes Care
Dec 21Is DexCom (NASDAQ:DXCM) Using Too Much Debt?
Dec 13Returns At DexCom (NASDAQ:DXCM) Are On The Way Up
Nov 04DexCom's Price: With The New G7 System And Partnerships, It May Spike Up
Oct 08Here's Why We Think DexCom (NASDAQ:DXCM) Is Well Worth Watching
Sep 30Shareholder Returns
| DXCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -9.2% | -3.1% | -3.1% |
| 1Y | 8.5% | 6.1% | 15.1% |
Return vs Industry: DXCM exceeded the US Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: DXCM underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: DXCM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DXCM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 7,550 | Kevin Sayer | https://www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
DexCom, Inc. Fundamentals Summary
| DXCM fundamental statistics | |
|---|---|
| Market Cap | US$33.94b |
| Earnings (TTM) | US$357.50m |
| Revenue (TTM) | US$3.20b |
94.9x
P/E Ratio10.6x
P/S RatioIs DXCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXCM income statement (TTM) | |
|---|---|
| Revenue | US$3.20b |
| Cost of Revenue | US$1.15b |
| Gross Profit | US$2.04b |
| Other Expenses | US$1.69b |
| Earnings | US$357.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 63.94% |
| Net Profit Margin | 11.18% |
| Debt/Equity Ratio | 152.6% |
How did DXCM perform over the long term?
See historical performance and comparison